Related references
Note: Only part of the references are listed.Serum YKL-40 levels are associated with type 2 diabetes mellitus in patients with obstructive sleep apnea syndrome
L. Sun et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Circulating biomarkers for gliomas
Manfred Westphal et al.
NATURE REVIEWS NEUROLOGY (2015)
Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR
Xavier Castells et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2015)
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
Rong Shao et al.
ONCOTARGET (2015)
Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus
Fumie Sakamoto et al.
ENDOCRINE JOURNAL (2013)
Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis
Maria Kazakova et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis
Aysegul Kucukali Turkyilmaz et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Elevated circulating levels of YKL-40 are a marker of abnormal glucose tolerance in women with polycystic ovary syndrome
Cem Celik et al.
CLINICAL ENDOCRINOLOGY (2012)
High YKL-40 Serum Concentration Is Correlated with Prognosis of Chinese Patients with Breast Cancer
Dong Wang et al.
PLOS ONE (2012)
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
A multigene predictor of outcome in glioblastoma
Howard Colman et al.
NEURO-ONCOLOGY (2010)
YKL-40 tissue expression and plasma levels in patients with ovarian cancer
Estrid V. S. Hogdall et al.
BMC CANCER (2009)
Plasma YKL-40: a potential new cancer biomarker?
Julia S. Johansen et al.
FUTURE ONCOLOGY (2009)
No association of (-131C→G) variant of CHI3L1 gene with risk of glioblastoma and prognosis
Blandine Boisselier et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
Adilia Hormigo et al.
CLINICAL CANCER RESEARCH (2006)
Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization
C Colin et al.
ONCOGENE (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
YKL-40 expression is associated with poorer response to radiation end shorter overall survival in glioblastoma
CE Pelloski et al.
CLINICAL CANCER RESEARCH (2005)
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma
JM Nigro et al.
CANCER RESEARCH (2005)
HC gp-39 gene is upregulated in glioblastomas
K Shostak et al.
CANCER LETTERS (2003)
Share Paper
